RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting
15 Juin 2023 - 10:15PM
RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a
specialty pharmaceutical company, today announced results of the
proposal to approve a waiver of offer obligations under Rule 9 of
the Irish Takeover Rules (the “Rules”) at the Company’s Annual
General Meeting held on June 15, 2023 (the “AGM”).
At the AGM, the resolution placed before the meeting in respect
of the approval of a waiver of offer obligations under Rule 9 of
the Rules to enable the acquisition of ordinary shares by the
Company’s major shareholders and certain members of its management
team was duly passed by independent shareholders of the Company on
a poll. The result of the poll was 36,568,508 votes for; and
390,152 votes against. There were 2,245,474 abstentions or withheld
votes.
Accordingly, the aggregate percentage shareholding in the
capital of the Company held by the parties specified in the table
below (and persons deemed to be acting in concert with them under
the Rules) (together, the “Affected Parties”) may proportionally
increase up to the maximum percentage specified below in the event
of the issue by the Company of up to 17,000,000 new ordinary
shares, US $0.01 nominal value per share, in the capital of the
Company. In such circumstances, the Affected Parties will not incur
an obligation under Rule 9 of the Rules to make a general offer to
the Company's other shareholders.
|
March 31, 2023
Shareholding (Number) |
March 31, 2023
Shareholding (%) |
Potential Shareholding Following
Share Issues (%) |
Avista Healthcare Partners, L.P. |
23,730,864 ordinary shares |
23.89% |
29.56% |
Altchem Limited and Orbit Co-Invest A-1 LLC |
23,667,540 ordinary shares |
23.82% |
29.50% |
Management Individuals (as defined in the Proxy
Statement) |
3,086,261 ordinary shares |
3.11% |
4.07% |
The full text of the resolution (being Proposal 3) is set out in
the Proxy Statement in respect of the AGM which is available at
https://www.rvlpharma.com.
About RVL Pharmaceuticals plcRVL
Pharmaceuticals plc is a specialty pharmaceutical company focused
on the commercialization of UPNEEQ® (oxymetazoline hydrochloride
ophthalmic solution), 0.1%, for the treatment of acquired
blepharoptosis, or droopy or low-lying eyelids, in adults. UPNEEQ
is the first non-surgical treatment option approved by the U.S.
Food and Drug Administration for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals
plc Lisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
RVL Pharmaceuticals (NASDAQ:RVLP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
RVL Pharmaceuticals (NASDAQ:RVLP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024